QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Google Scholar Articles by DiCenzo, R. Articles by Schifitto, G. PubMed PubMed Citation Articles by DiCenzo, R. Articles by Schifitto, G.

HIV/AIDS

Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in HIV-Infected Adults

Associate Professor, Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY; Infectious Disease Division, University of Rochester Medical Center, Rochester

Robin DiFrancesco, MBA

Laboratory Manager, University at Buffalo, Buffalo, NY

Kim Cruttenden, RN MS

Project Nurse, University of Rochester Medical Center

Julie Donnelly, BS

Research Technician, University at Buffalo

Giovanni Schifitto, MD

Associate Professor, University of Rochester Medical Center

Reprints: Dr. DiCenzo, Wegmans School of Pharmacy, St. John Fisher College, 3690 E. Ave., Rochester, NY 14618, fax 585/385-5295, rdicenzo{at}sjfc.edu

BACKGROUND: The central nervous system may act as a sanctuary site for viral replication in the setting of low antiretroviral penetration. Data on lopinavir cerebrospinal fluid (CSF) trough concentration (C_trough) values have yet to be reported.

OBJECTIVE: To describe lopinavir CSF C_trough values and compare them with a measure of HIV susceptibility.

METHODS: In a prospective, open-label design, HIV-infected adults whose regimen included lopinavir/ritonavir 400/100-mg soft-gel capsules twice daily for at least 4 weeks were enrolled. Each subject had 8 plasma lopinavir concentrations determined over a 12-hour dosing interval and 1 CSF lopinavir C_trough value determined at the end of the study. Linear regression methods tested for associations between CSF or CSF to plasma concentration ratio and covariates including pharmacokinetic parameters and CSF protein.

RESULTS: Ten patients (7 male; median [range] ± SD age 45.3 ± 2.8 y) completed the study. Median (intraquartile range [IQR]) lopinavir plasma 0- to 12-hour area under the curve (AUC_0-12) and minimum concentrations were 71.3 h·µg/mL (48.4–87.6) and 3.82 µg/mL (2.76–5.34). Median (IQR) CSF C_trough, paired plasma concentration, and time since last dose were 11,200 pg/mL (6760–16,400), 5.42 µg/mL (3.88–5.85), and 9.9 hours (9.7–10.2), respectively. Median (IQR) CSF to plasma concentration ratio was 0.225% (0.194–0.324). Lopinavir CSF C_trough was above the median 50% inhibitory concentration (IC₅₀) for wild-type HIV-1 (wtHIV-1) (1900 pg/mL) in all subjects. Lopinavir plasma AUC_0-12 (r² = 0.65; p = 0.009) and CSF protein (r² = 0.26; p = 0.006) were associated with lopinavir CSF concentration, while CSF protein (r² = 0.66; p = 0.008) was associated with CSF to plasma concentration ratio.

CONCLUSIONS: Lopinavir CSF C_trough was above the median IC₅₀ for wtHIV-1 replication in all patients receiving lopinavir/ritonavir 400/100-mg soft-gel capsules twice daily.

Key Words: cerebrospinal fluid, HIV, lopinavir, pharmacokinetics, trough concentration

Published Online, November 24, 2009. www.theannals.com, DOI 10.1345/aph.1M399